EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

6-month Progression-Free Survival (PFS6) as a prognostic factor in large B-cell lymphoma patients undergoing chimeric antigen receptor T-cell therapy: A real-world multicenter study

Zhangyan Wang, Xiaoshi Liu, Huangming Hong, Tongyu Lin

Annals of Hematology · 14.03.2026 · 105 (4)

DOI: 10.1007/s00277-026-06910-8 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Hematology, online erschienen am 14.03.2026. Verfasst von Zhangyan Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital and I…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Receptors, Chimeric Antigen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the National Natural Science Foundation of China, Cancer Innovative Research Program of Sun Yat-sen University Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseReceptors, Chimeric AntigenAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisProgression-Free SurvivalRetrospective Studies

Stichwörter der Autor:innen

6-month progression-free survivalCAR-T therapyOverall survivalR/R LBCL

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital and Institute, University of Electronic Science and Technology of China, Ch…
  • Department of Gynecologic Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, Sichuan, Ch…
  • Department of Oncology, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China.
  • Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China. linty@sysucc.org.cn.

Förderung

  • the National Natural Science Foundation of China
  • Cancer Innovative Research Program of Sun Yat-sen University Cancer Center

Zitieren

APA

Wang, Z., Liu, X., Hong, H., & Lin, T. (2026). 6-month Progression-Free Survival (PFS6) as a prognostic factor in large B-cell lymphoma patients undergoing chimeric antigen receptor T-cell therapy: A real-world multicenter study. Annals of Hematology, 105(4). https://doi.org/10.1007/s00277-026-06910-8

Vancouver

Wang Z, Liu X, Hong H, Lin T. 6-month Progression-Free Survival (PFS6) as a prognostic factor in large B-cell lymphoma patients undergoing chimeric antigen receptor T-cell therapy: A real-world multicenter study. Annals of Hematology. 2026;105(4). doi:10.1007/s00277-026-06910-8

BibTeX
@article{Wang2026,
  author = {Wang, Zhangyan and Liu, Xiaoshi and Hong, Huangming and Lin, Tongyu},
  title = {6-month Progression-Free Survival (PFS6) as a prognostic factor in large B-cell lymphoma patients undergoing chimeric antigen receptor T-cell therapy: A real-world multicenter study},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {4},
  doi = {10.1007/s00277-026-06910-8}
}
Kostenlos starten →